Developmental Therapeutic Unit

Introducing DTU


The NCIS DTU : A multidisciplinary team at the cutting edge of cancer care


The NCIS DTU comprises a team of clinicians, nurses, allied health professionals and scientists, who work in a multi-disciplinary team to ensure utmost standards of safety in conducting early phase trials.

The DTU team currently run a dedicated clinic every Monday and Thursday and meet weekly to discuss the clinical progress of each DTU patient on studies and any other trial related issues. Through the YSY grant, we have also been able to develop a training fellowship program in cancer drug development in the DTU.

Placeholder

About DTU


The establishment of the NCIS DTU has already helped attract interest from drug companies seeking academic partners who have the appropriate infrastructure in place to support early phase trials in Asia. This has in turn benefited our patients by giving them access to cutting-edge anti-cancer drugs. Currently ongoing clinical trials of novel compounds in the DTU are shown in Table 1.

All of our medical oncologists in the team are also leading experts in specific tumour types and hence provide added clinical and scientific insights into the management of each patient referred to the DTU.

Given that many of the currently tested compounds target a specific molecular pathway aberration in cancer cells, patients in our DTU early phase trials are also offered molecular profiling of their tumours via our integrated molecular analysis of cancer (IMAC) program to identify these “actionable” molecular aberrations in the tumour cells so that, based on their tumour molecular profile, patients can then be matched to the most appropriate drug in early phase clinical trials.

Finding and developing the next generation of anti-cancer drugs. The next era of oncological therapy will inevitably evolve from a better understanding of the molecular aberrations in cancers allied with technologies that will facilitate a rapid and comprehensive characterization of the unique biological features of each cancer patient’s tumour. The challenge for oncologists is to leverage on this wealth of scientific information to develop more effective therapeutic options for patients via well-designed and expertly executed early phase studies. The NCIS DTU is now fully equipped to embrace this challenge and lead the development of new drugs in the fight against cancer.

Table 1: DTU Phase 1 Trials 2016

  • Connector.

    P-TEFb Inhibitor (Bayer)

    This is an Feature List Item that is part of an Feature List. Notice the connector between the three graphics to show that they are related.

  • Connector.

    Trastuzumab + NK-Cell Therapy for HER2 Amplified/Overexpressed Tumors

    This is an Feature List Item that is part of an Feature List. Notice the connector between the three graphics to show that they are related.

  • Connector.

    Balanced PI3Kα/β inhibitor (Bayer)

    This is an Feature List Item that is part of an Feature List. Notice the connector between the three graphics to show that they are related.

  • Connector.

    Exportin 1 (XPO1) inhibitor – selective inhibitor of nuclear export (Selinexor, Karyopharm)

    This is an Feature List Item that is part of an Feature List. Notice the connector between the three graphics to show that they are related.

  • Connector.

    PDL-1 + MEK inhibitor (Roche)

    This is an Feature List Item that is part of an Feature List. Notice the connector between the three graphics to show that they are related.

  • Connector.

    Pan-fibroblast growth factor receptor (FGFR) inhibitor (Bayer)

    This is an Feature List Item that is part of an Feature List. Notice the connector between the three graphics to show that they are related.

  • Connector.

    AKT1 inhibitor (Astra Zeneca) in tumours with AKT1 mutations

    This is an Feature List Item that is part of an Feature List. Notice the connector between the three graphics to show that they are related.

  • Connector.

    ASLAN001: HER1/2/4 inhibitor + carboplatin and paclitaxel

    This is an Feature List Item that is part of an Feature List. Notice the connector between the three graphics to show that they are related.

  • Connector.

    PLK1 inhibitor (Tekmira)

    This is an Feature List Item that is part of an Feature List. Notice the connector between the three graphics to show that they are related.

  • Connector.

    Wnt/Porc inhibitor (Experimental Therapeutics Centre/D3 A*STAR Singapore)

    This is an Feature List Item that is part of an Feature List. Notice the connector between the three graphics to show that they are related.